Added to YB: 2026-07-27
Pitch date: 2026-07-24
NKTR [neutral]
Nektar Therapeutics
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally.
Market Cap
$2.3B
Pitch Price
N/A
Price Target
80.00
Dividend
N/A
EV/EBITDA
-15.19
P/E
-8.57
EV/Sales
31.55
Sector
Pharmaceuticals
Category
special_situation
Show full summary:
$NKTR Quick Update
NKTR (update): Potential catalyst in <6 weeks where cash pile rises 20-50%, fully funding Ph3s for AA & AtD. Improves partnership negotiating position & removes legal overhang for smoother M&A. Trades under $70; author sees floor at $80.
Read full article (1 min)